Hormone Replacement Therapy (‘HRT“) medications have been for many years prescribed by doctors to ease symptoms and effects of menopause. Many women with an intact uterus who chose to take HRT medication to ease symptoms of menopause used the two tablet therapy of PREMARIN® (conjugated estrogens tablets) and PROVERA ® (medroxyprogesterone acetate tablets) until the single tablet therapy of PREMPROTM (conjugated estrogens / medroxyprogesterone acetate tablets) was developed.
It is believed that many of the manufacturers of HRT promoted and encouraged long-term use of their products despite serious questions about their promotional claims for which there was no adequate clinical study. The Federal government intervened in and funded a series of studies to determine the safety and the effectiveness of these products. One of these studies was conducted by the Women’s Health Initiative (WHI) a program established by the National Institute of Health to research quality of life issues in women. A report released in 2002 by the WHI showed that, women taking the combination estrogen plus progesterone HRT medication developed breast cancer more often then those taking placebo (inactive) pills. The breast cancer in the combination estrogen plus progesterone HRT group tended to be more invasive and more advanced. The types of breast cancer women developed ranged from Lobular to Ductal Invasive Carcinoma, which was both estrogen and progesterone positive. In reaction to the 2002 report the FDA required the manufacturers of PREMPROTM and similar estrogen plus progesterone products to introduce new labeling warning of the risks.
At Ury & Moskow, LLC, we are actively prosecuting cases on behalf of women who were injured by these drugs and who have developed Invasive Ductal Carcinoma, which are both estrogen and progesterone positive, and Lobular type breast cancer.